Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

317 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The role of protein traffic in the progression of renal diseases.
Ruggenenti P, Remuzzi G. Ruggenenti P, et al. Annu Rev Med. 2000;51:315-27. doi: 10.1146/annurev.med.51.1.315. Annu Rev Med. 2000. PMID: 10774467 Review.
Prognosis of diabetic nephropathy: how to improve the outcome.
Remuzzi G, Ruggenenti P. Remuzzi G, et al. Among authors: ruggenenti p. Diabetes Res Clin Pract. 1998 Apr;39 Suppl:S49-53. doi: 10.1016/s0168-8227(98)00016-3. Diabetes Res Clin Pract. 1998. PMID: 9649960 Review.
Renin-angiotensin system, proteinuria, and tubulointerstitial damage.
Ruggenenti P, Aros C, Remuzzi G. Ruggenenti P, et al. Contrib Nephrol. 2001;(135):187-99. doi: 10.1159/000060166. Contrib Nephrol. 2001. PMID: 11705284 Review. No abstract available.
Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease.
Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, de Jong PE, de Zeeuw D, Shahinfar S, Ruggenenti P, Remuzzi G, Levey AS; AIPRD Study Group. Angiotensin-Converting Enzymne Inhibition and Progression of Renal Disease. Jafar TH, et al. Among authors: ruggenenti p. Kidney Int. 2001 Sep;60(3):1131-40. doi: 10.1046/j.1523-1755.2001.0600031131.x. Kidney Int. 2001. PMID: 11532109 Clinical Trial.

Patients with higher baseline urine protein excretion values had a greater reduction in proteinuria during the follow-up in association with treatment with ACE inhibitors and in association with lowering systolic and diastolic blood pressures (interaction P < 0.001 for

Patients with higher baseline urine protein excretion values had a greater reduction in proteinuria during the follow-up in association with …
ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies1.
Perna A, Ruggenenti P, Testa A, Spoto B, Benini R, Misefari V, Remuzzi G, Zoccali C. Perna A, et al. Among authors: ruggenenti p. Kidney Int. 2000 Jan;57(1):274-81. doi: 10.1046/j.1523-1755.2000.00818.x. Kidney Int. 2000. PMID: 10620209 Clinical Trial.
Either at univariate (P = 0.04) or at multivariate (P = 0.01) analysis, ramipril significantly predicted a lower incidence of events in DD, but not in II and ID patients. ...In DD (but not in II or ID) ramipril-treated patients, a short-term reduction in proteinuria …
Either at univariate (P = 0.04) or at multivariate (P = 0.01) analysis, ramipril significantly predicted a lower incidence of …
ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome.
Ruggenenti P, Mosconi L, Vendramin G, Moriggi M, Remuzzi A, Sangalli F, Remuzzi G. Ruggenenti P, et al. Am J Kidney Dis. 2000 Mar;35(3):381-91. doi: 10.1016/s0272-6386(00)70190-9. Am J Kidney Dis. 2000. PMID: 10692263 Clinical Trial.

However, in patients at the end of the treatment period, MAP (posttreatment, 99.6 +/- 11.2 versus basal, 103.3 +/- 12.1 mm Hg; P < 0.05), proteinuria (posttreatment protein, 5.0 +/- 2.9 versus basal, 7.1 +/- 4.9 g/24 h; P < 0.05), albumin fractional clearance

However, in patients at the end of the treatment period, MAP (posttreatment, 99.6 +/- 11.2 versus basal, 103.3 +/- 12.1 mm Hg; P < …
Progression, remission, regression of chronic renal diseases.
Ruggenenti P, Schieppati A, Remuzzi G. Ruggenenti P, et al. Lancet. 2001 May 19;357(9268):1601-8. doi: 10.1016/S0140-6736(00)04728-0. Lancet. 2001. PMID: 11377666 Review.
Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.
Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G. Ruggenenti P, et al. Lancet. 1999 Jul 31;354(9176):359-64. doi: 10.1016/S0140-6736(98)10363-X. Lancet. 1999. PMID: 10437863 Clinical Trial.
Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy.
Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Ruggenenti P, et al. Lancet. 1998 Oct 17;352(9136):1252-6. doi: 10.1016/s0140-6736(98)04433-x. Lancet. 1998. PMID: 9788454 Clinical Trial.
FINDINGS: During the follow-up study the mean rate of GFR decline per month decreased from 0.44 (SD 0.54) mL/min per 1.73 m2 in the core study to 0.10 (0.50) mL/min per 1.73 m2 in patients originally randomised to ramipril (p=0.017), and from 0.81 (1.12) to 0.14 (0.87) mL/ …
FINDINGS: During the follow-up study the mean rate of GFR decline per month decreased from 0.44 (SD 0.54) mL/min per 1.73 m2 in the core stu …
Methods of cardio-renal protection in non-diabetic chronic nephropathies.
Ruggenenti P, Remuzzi G. Ruggenenti P, et al. Rocz Akad Med Bialymst. 2004;49:116-23. Rocz Akad Med Bialymst. 2004. PMID: 15631326 Review.
317 results
Jump to page
Feedback